AstraZeneca reports disappointing Phase 3 data for lung cancer ADC (NASDAQ:AZN)

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) stated {that a} Part 3 research of their antibody drug conjugate, or ADC, datopotamab deruxtecan didn’t present it was in a position to considerably prolong lives versus the chemotherapy drug docetaxel. Whereas the research’s outcomes for total survival favored the drug, also called Dato-DXd, they didn’t attain statistical significance, in accordance with a press release. The info did present, nevertheless, a 2.3 month enchancment for Dato-DXd sufferers with non-squamous non-small cell lung most cancers, or NSCLC, with total survival of 14.6 months, in contrast with 12.3 months for sufferers given docetaxel. In sufferers with squamous NSCLC, no total survival enchancment was noticed. Shares of AstraZeneca closed 3% decrease on Monday following the information.